PHA-797804

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H19BrF2N2O3
Molecular Weight	477.299
Optical Activity	NONE
Additional Stereochemistry	Yes
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0
Stereo Comments	AXIAL, RACEMIC

SHOW SMILES / InChI

Structure Search

SMILES

CNC(=O)C1=CC=C(C)C(=C1)N2C(C)=CC(OCC3=CC=C(F)C=C3F)=C(Br)C2=O

InChI

InChIKey=KCAJXIDMCNPGHZ-UHFFFAOYSA-N

InChI=1S/C22H19BrF2N2O3/c1-12-4-5-14(21(28)26-3)9-18(12)27-13(2)8-19(20(23)22(27)29)30-11-15-6-7-16(24)10-17(15)25/h4-10H,11H2,1-3H3,(H,26,28)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19720877 | https://www.ncbi.nlm.nih.gov/pubmed/19496616

PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein. The drug was developed by Pfizer for the treatment of inflammatory diseases. PH-797804 is being tested in phase II of clinical trials in patients with COPD, osteoarthritis, rheumatoid arthritis and post-herpetic neuralgia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
MAP kinase p38 alpha 34 Target ID: CHEMBL260 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21641211	Inhibitor 8504		2.3 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Chronic obstructive pulmonary disease 175 Sources: https://clinicaltrials.gov/ct2/show/NCT00559910	Primary	Phase II 1147	Unknown Approved Use Unknown
Postherpetic neuralgia 13 Sources: https://clinicaltrials.gov/ct2/show/NCT00614705	Primary	Phase II 1147	Unknown Approved Use Unknown
Rheumatoid arthritis 320 Sources: https://clinicaltrials.gov/ct2/show/NCT00383188	Palliative	Phase II 1147	Unknown Approved Use Unknown
Osteoarthritis of knee 23 Sources: https://clinicaltrials.gov/ct2/show/NCT01102660	Palliative	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
38.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26265232/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		PHA-797804 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00EFQA	https://www.1pchem.com/search?query=1P00EFQA
AK Scientific	X7463	https://aksci.com/item_detail.php?cat=X7463
Angene	AGN-PC-0SQ758	http://www.angenechemical.com/productshow/AGN-PC-0SQ758.html
ApexBio Technology	A8308	https://www.apexbt.com/catalogsearch/result/?q=A8308
Axon MedChem	1837	https://www.axonmedchem.com/product/1837
Axon MedChem	2786	https://www.axonmedchem.com/product/2786
BOC Sciences	586379-66-0	http://www.bocsci.com/description.asp?cas=586379-66-0
Cayman Chemical	20244	http://www.caymanchem.com/app/template/Product.vm/catalog/20244
Chem Scene	CS-0465	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0465
ChemShuttle	109802	https://www.chemshuttle.com/catalogsearch/result/?q=109802
eMolecules	37153213	https://orderbb.emolecules.com/search/#?query=37153213
eNovation Chemicals	D518772	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D518772&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A2344	http://www.excenen.com/searchresultlist.php?id=EX-A2344
Hairui	HR110180	http://www.hairuichem.com/en/product/search.do?q=HR110180
Matrix Scientific	97267	http://www.matrixscientific.com/097267.html
mcule	MCULE-9395102749	https://mcule.com/MCULE-9395102749/
MedChem Express	HY-10403	https://www.medchemexpress.com/search.html?q=HY-10403&ft=&fa=&fp=
Molnova	M15158	https://www.molnova.com/en/serch-list.html?keywords=M15158
MolPort	MolPort-021-804-991	https://www.molport.com/shop/molecule-link/MolPort-021-804-991
MuseChem	R024553	https://www.musechem.com/product/R024553.html
Ryan Scientific	Diclofenac_Amide	https://ryansci.com/products?q=Diclofenac_Amide&list_q=&search_type=exact
Selleck Chemicals	S2726	http://www.selleckchem.com/search.html?searchDTO.searchParam=S2726
ShangHai Biochempartner	BCP000284	http://www.biochempartner.com/search_BCP000284
ShangHai Biochempartner	BCP02266	http://www.biochempartner.com/search_BCP02266
TargetMol	T1974	https://www.targetmol.com/search?keyword=T1974
Toronto Research Chemicals	F594505	https://www.trc-canada.com/product-detail/?CatNum=F594505
Toronto Research Chemicals	P399150	https://www.trc-canada.com/product-detail/?CatNum=P399150

PubMed

Title	Date	PubMed
		252160496
Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.	2011 Jul 1	21641211
Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.	2011 Jul 1	21620699
Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.	2011 Nov 24	21888439

Patents

Sample Use Guides

In Vivo Use Guide

Chronic Obstructive Pulmonary Disease: PH-797804 should be orally administered at maximum dose of 10 mg. Neuralgia: 6 mg dose in oral capsule form, once daily for 28 days. Osteoarthritis: 6 mg once daily for 2 weeks. Rheumatoid Arthritis: the maximum dose is 10 mg taken once daily for 12 weeks.

Route of Administration: Oral

In Vitro Use Guide

Rheumatoid arthritis synovial fibroblasts were treated with serial concentrations (10000–0.01 nM) of PH-797804 for 1 h, stimulated with 1 ng/ml IL-1 for 18 to 20 h at 37C to measure IL-1-beta induced PGE2 production. IC50 was 1.5 nM.

Name

Type

Language

PHA-797804

Code

English

PH 797804

Preferred Name

English

BENZAMIDE, 3-(3-BROMO-4-((2,4-DIFLUOROPHENYL)METHOXY)-6-METHYL-2-OXO-1(2H)-PYRIDINYL)-N,4-DIMETHYL-

Systematic Name

English

PH797804

Code

English

Code System Code Type Description

EPA CompTox

DTXSID70207342